Daan Knapen

Zoekresultaten

• 2022

  Abstract CT207: A phase 1 open-label, dose escalation and expansion trial to investigate the safety, pharmacokinetics and pharmacodynamics of CB307, a Trispecific Humabody® T-cell enhancer, in patients with PSMA+ advanced and/or metastatic solid tumors (POTENTIA)

  de Bono, J. S., Arkenau, H-T., Gort, E. H., Devriese, L. L., Fontana, E., Knapen, D. G., Tiu, C., Williams, A., de Groot, D. J. A., Gunaydin, U. M., Bartlett, P., Pierce, A. J., Bland-Ward, P., Hashimoto, K. & de Vries, E. G. E., 1-jun.-2022, In: Cancer Research. 82, 12_Supplement, blz. CT207-CT207

  Onderzoeksoutput › Academic